# A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

> **NCT05806567** · PHASE1 · COMPLETED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 52 (actual)

## Conditions studied

- Immune System Disorder
- Healthy Volunteers

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** UGT1A1 victim drug
- **DRUG:** P-gp victim drug
- **DRUG:** OATP1B1/BCRP victim drug

## Key facts

- **NCT ID:** NCT05806567
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-27
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-28
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806567, "A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05806567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*